What is the recommended Vyvanse (lisdexamfetamine) dosing regimen for patients aged 6 years and older, including starting dose, titration increments, maximum dose, and adjustments for cardiovascular disease, hypertension, severe anxiety, or amphetamine sensitivity?

Recommended Vyvanse Dosing

Start Vyvanse at 30 mg once daily in the morning for both children (≥6 years) and adults, titrate weekly by 10-20 mg increments as needed, with a maximum dose of 70 mg/day for most patients. 1

Starting Dose and Administration

• Initial dose: 30 mg once every morning for all patients aged 6 years and older (both ADHD and binge eating disorder) 1
• Administer in the morning; can be taken with or without food
• The prodrug design provides approximately 12-13 hours of symptom control 2, 3

Titration Schedule

Weekly titration is recommended:

• Increase by 10 mg or 20 mg per week based on clinical response and tolerability 1
• Therapeutic range: 30-70 mg/day
• Maximum dose: 70 mg/day for patients with normal renal function 1

The FDA label provides clear guidance that differs from older stimulant guidelines which recommended starting with lower doses of immediate-release amphetamines (2.5 mg) 4. Vyvanse's prodrug formulation allows for a higher, standardized starting dose across age groups.

Renal Impairment Adjustments

Critical dosing modifications are required for kidney disease:

• Severe renal impairment (GFR 15-29 mL/min): Maximum 50 mg/day 1
• End-stage renal disease (ESRD, GFR <15 mL/min): Maximum 30 mg/day 1

These are hard limits, not suggestions—exceeding these doses in renally impaired patients increases toxicity risk.

Contraindications and High-Risk Situations

Absolute contraindications (do not prescribe):

• Previous hypersensitivity to amphetamine products 4
• Current or recent (within 14 days) MAO inhibitor use 4
• Active psychotic disorder 4

Relative contraindications requiring careful assessment:

• Symptomatic cardiovascular disease - Vyvanse is contraindicated 4. Recent evidence shows long-term stimulant use (>3 years) increases cardiovascular event risk, particularly hypertension and arterial disease 5
• Hypertension - Vyvanse increases systolic BP by ~2 mmHg and diastolic BP by ~2 mmHg 6. Patients with uncontrolled hypertension should not receive stimulants 4
• Atherosclerotic heart disease - Carries the highest risk for adverse cardiovascular events (aOR 36.7) 7

Contrary to older package insert warnings, severe anxiety, tics, and Tourette's disorder are no longer considered absolute contraindications based on recent clinical trial data, though caution is warranted 4.

Pre-Treatment and Monitoring Requirements

Before initiating Vyvanse:

• Obtain baseline blood pressure, pulse, height, and weight 4
• Assess for cardiac disease - this is mandatory per FDA labeling 1
• Screen for personal or family history of stimulant abuse
• In adolescents, assess for substance abuse 8

During treatment:

• Monitor blood pressure and pulse quarterly in adults 4
• Check vital signs annually in children during routine physical exams 4
• Assess for treatment-emergent adverse effects systematically: insomnia, decreased appetite, headache, irritability 2, 3
• Monitor weight at each visit as objective measure of appetite suppression 4

Special Populations

Adolescents:

• Consider formulations with lower abuse potential like lisdexamfetamine (Vyvanse) for patients at risk of diversion 8
• Provide medication coverage for driving hours—consider timing of dose or late-afternoon supplementation 8

Adults:

• Same dosing as children: start 30 mg, titrate to 30-70 mg/day 1
• Response rates are similar in treatment-naïve patients and those who failed previous methylphenidate trials 9

Preschool children (<6 years):

• Vyvanse is not FDA-approved for this age group 1
• If stimulants are needed, dextroamphetamine is the only FDA-approved option, though evidence is limited 8

Common Pitfalls to Avoid

• Don't start at subtherapeutic doses: Unlike immediate-release amphetamines that start at 2.5 mg, Vyvanse should begin at 30 mg 1
• Don't exceed renal dosing limits: This is a hard ceiling, not a guideline 1
• Don't ignore cardiovascular screening: Baseline cardiac assessment is mandatory, not optional 1
• Don't assume tolerance to cardiovascular effects: Blood pressure elevation persists with chronic use (≥8 weeks), requiring ongoing monitoring 6
• Don't prescribe with uncontrolled hypertension or symptomatic heart disease: These are contraindications 4

Duration of Effect and Practical Considerations

Vyvanse demonstrates efficacy from 1.5 hours post-dose through 13 hours, providing full-day coverage including homework and evening activities 2. This once-daily dosing improves adherence compared to multiple-daily-dose immediate-release formulations and reduces the need for school-based medication administration.

The prodrug design (requiring enzymatic conversion to active d-amphetamine) theoretically reduces abuse potential compared to immediate-release amphetamines, though withdrawal rates due to adverse effects remain elevated (risk ratio 2.69) 6.